Pfizer’s sickle cell disease candidate fails Phase III trial

Inclacumab was generally well tolerated in THRIVE-131

AbbVie to invest $195 million to expand API manufacturing in North Chicago

The new facility will enhance AbbVie’s chemical synthesis capacity to support domestic production of current and next-generation neuroscience, immunology, and oncology medicines

Cohance to invest $10 million to expand cGMP bioconjugation capabilities in US

NJ Bio is currently executing a major new program for an existing innovator customer with multiple ADC candidates in their pipeline

AbbVie submits for FDA approval of Venclexta and Acalabrutinib combination for untreated CLL patients

The submission is supported by positive results from the Phase 3 AMPLIFY trial

AbbVie announces positive Phase 3 results for Upadacitinib in Alopecia Areata

The average baseline SALT score was 83.8, indicating about 16% scalp hair coverage

Sanofi’s GPRC5D monoclonal antibody earns ODD in US for multiple myeloma

Illumina launches new assay for tumor profiling

he new version features a streamlined sample-to-analysis workflow, built-in HRD detection, faster turnaround, and lower tissue requirements

GlaxoSmithKline Pharmaceuticals reports Q1 FY26 PAT at Rs. 205 Cr

The performance was below anticipated levels, primarily due to external factors such as seasonal disruption that affected overall results

Bristol Myers Squibb and Bain Capital launch biotech company NewCo

NewCo’s pipeline includes five investigational medicines

Imfinzi granted Priority Review and Breakthrough Therapy Designation in US

For patients with resectable early-stage gastric and gastroesophageal junction cancers